AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21919823 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous alemtuzumab 10 mg three times a week for 18 weeks
Number of subjects: 39
Study 21919823 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous alemtuzumab 30 mg once weekly after lymphocyte count reduction by 1 Log in 18 patients
Number of subjects: 39
Study 21919823 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous alemtuzumab
Number of subjects: 39
Study 20584263 — intervention group
Group type: EXPERIMENTAL
Intervention: Tagatose at 250 mOsmol
Number of subjects: 31
Study 20584263 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructose at 250 mOsmol
Number of subjects: 31
Study 20584263 — intervention group
Group type: COMPARATOR
Intervention: All hexoses at 500 mOsmol
Number of subjects: 31
Study 20584263 — intervention group
Group type: COMPARATOR
Intervention: Lactulose and saline at 500 mOsmol
Number of subjects: 31
Study 18758414 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined anesthesia (isoflurane anesthesia combined with thoracic epidural analgesia)
Number of subjects: 60
Study 18758414 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane/fentanyl anesthesia
Number of subjects: 60
Study 18758414 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined anesthesia
Number of subjects: 60
Study 18758414 — intervention group
Group type: COMPARATOR
Intervention: Combined anesthesia and Isoflurane/fentanyl anesthesia
Number of subjects: 60
Study 16002961 — intervention group
Group type: EXPERIMENTAL
Intervention: EBUS-D
Number of subjects: 55
Study 16002961 — intervention group
Group type: COMPARATOR
Intervention: EBUS-S
Number of subjects: 55
Study 12466508 — intervention group
Group type: EXPERIMENTAL
Intervention: Diethylcarbamazine plus ivermectin
Number of subjects: 2500
Study 12466508 — intervention group
Group type: EXPERIMENTAL
Intervention: Diethylcarbamazine alone
Number of subjects: 2500
Study 12466508 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 2500
Study 10730524 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh Frozen Plasma (FFP)
Number of subjects: 64
Study 10730524 — intervention group
Group type: EXPERIMENTAL
Intervention: Haemaccel
Number of subjects: 64
Study 10730524 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal Saline (NSS)
Number of subjects: 64
Study 10730524 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 64
Study 7718260 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate
Number of subjects: 50
Study 7718260 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 1674060 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy for severe stenosis (70-99%)
Number of subjects: 2200
Study 1674060 — intervention group
Group type: COMPARATOR
Intervention: Control group (no surgery) for severe stenosis (70-99%)
Number of subjects: 2200
Study 7470781 — intervention group
Group type: EXPERIMENTAL
Intervention: Amipaque (metrizamide)
Number of subjects: 0
Study 7470781 — intervention group
Group type: EXPERIMENTAL
Intervention: Amipaque (metrizamide) 370 mg iodine/ml
Number of subjects: 0
Study 7470781 — intervention group
Group type: EXPERIMENTAL
Intervention: Amipaque (metrizamide) 300 mg iodine/ml
Number of subjects: 0
Study 31170151 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous experience of physical IPV
Number of subjects: 0
Study 31170151 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous experience of emotional IPV
Number of subjects: 0
Study 31170151 — intervention group
Group type: EXPERIMENTAL
Intervention: Home violence
Number of subjects: 0
Study 31170151 — intervention group
Group type: EXPERIMENTAL
Intervention: High self-efficacy
Number of subjects: 0
Study 28779269 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-heme iron (FeSO4, 195 mg/day)
Number of subjects: 14
Study 28779269 — intervention group
Group type: COMPARATOR
Intervention: Heme iron (heme-iron-polypeptide, HIP, 31.5 to 94.5 mg/day)
Number of subjects: 14
Study 27129315 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper tertile U-Cd (≥0.42 μg/g Cr)
Number of subjects: 653
Study 27129315 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased U-Cd concentrations
Number of subjects: 653
Study 27129315 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intake of micronutrients (calcium, magnesium, zinc, and selenium)
Number of subjects: 653
Study 27129315 — intervention group
Group type: COMPARATOR
Intervention: Preeclamptic women
Number of subjects: 653
Study 24367008 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrates (specifically intravenous nitroglycerin infusion)
Number of subjects: 199
Study 24367008 — intervention group
Group type: COMPARATOR
Intervention: No nitrates (control group)
Number of subjects: 199
Study 24367008 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrates (general use)
Number of subjects: 199
Study 24367008 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous nitroglycerin infusion
Number of subjects: 199
Study 22077907 — intervention group
Group type: EXPERIMENTAL
Intervention: Supported Employment (SE)
Number of subjects: 100
Study 22077907 — intervention group
Group type: COMPARATOR
Intervention: Traditional Vocational Rehabilitation (TVR)
Number of subjects: 100
Study 20392784 — intervention group
Group type: EXPERIMENTAL
Intervention: Locomotor imagery training (five days a week for four weeks)
Number of subjects: 24
Study 20392784 — intervention group
Group type: EXPERIMENTAL
Intervention: Locomotor imagery training
Number of subjects: 24
Study 20392784 — intervention group
Group type: COMPARATOR
Intervention: Control group (regular physical therapy)
Number of subjects: 24
Study 20392784 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 24
Study 17582407 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy consisting of prednisolone, L-thyroxine, and conjugated estrogen/medroxyprogesterone acetate
Number of subjects: 0
Study 17582407 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 0
Study 15598939 — intervention group
Group type: EXPERIMENTAL
Intervention: TAC (docetaxel 75 mg/m(2), doxorubicin 50 mg/m(2), cyclophosphamide 500 mg/m(2) every 21 days)
Number of subjects: 285
Study 15598939 — intervention group
Group type: COMPARATOR
Intervention: NX (vinorelbine 25 mg/m(2) days 1 and 8, capecitabine 2000 mg/m(2) days 1‐14, every 21 days)
Number of subjects: 285
Study 12680746 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 9
Study 12680746 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 10736083 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal codeine phosphate (1 mg.kg‐1)
Number of subjects: 20
Study 10736083 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular codeine phosphate (1 mg.kg‐1)
Number of subjects: 20
Study 8706304 — intervention group
Group type: EXPERIMENTAL
Intervention: GH alone (32 children)
Number of subjects: 50
Study 8706304 — intervention group
Group type: EXPERIMENTAL
Intervention: GH plus oxandrolone (8 children)
Number of subjects: 50
Study 8706304 — intervention group
Group type: EXPERIMENTAL
Intervention: GH plus testosterone (4 children)
Number of subjects: 50
Study 8706304 — intervention group
Group type: COMPARATOR
Intervention: Placebo (6 children)
Number of subjects: 50
Study 1439070 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide 5‐Mononitrate 50 mg sustained release administered once daily
Number of subjects: 10
Study 3510797 — intervention group
Group type: COMPARATOR
Intervention: Ketorolac 20 mg
Number of subjects: 0
Study 3510797 — intervention group
Group type: COMPARATOR
Intervention: Ketorolac 10 mg
Number of subjects: 0
Study 3510797 — intervention group
Group type: COMPARATOR
Intervention: Acetaminophen 1000 mg
Number of subjects: 0
Study 3510797 — intervention group
Group type: COMPARATOR
Intervention: Acetaminophen 500 mg
Number of subjects: 0
Study 3510797 — intervention group
Group type: COMPARATOR
Intervention: Ketorolac (5 mg, 10 mg)
Number of subjects: 0
Study 31522153 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined orthodontic regenerative therapy with laser irradiation (Group I: test group)
Number of subjects: 15
Study 31522153 — intervention group
Group type: COMPARATOR
Intervention: Combined orthodontic regenerative therapy alone (Group II: control group)
Number of subjects: 15
Study 29921056 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal analgesia (parrixibub sodium 40 mg intravenously 0.5 h before surgery, oxygen budesonide aerosol inhalation therapy after surgery, sodium aescinate 10 mg intravenously at 24, 48, 72 h after surgery)
Number of subjects: 90
Study 29921056 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal analgesia
Number of subjects: 90
Study 27196567 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ixazomib 3 mg
Number of subjects: 41
Study 23231377 — intervention group
Group type: EXPERIMENTAL
Intervention: Nintendo Wii balance training
Number of subjects: 3
Study 23231377 — intervention group
Group type: COMPARATOR
Intervention: Traditional balance therapy
Number of subjects: 3
Study 22130395 — intervention group
Group type: EXPERIMENTAL
Intervention: Recovery after a maximal 30‐second sprint with rest intervals of 5, 10, 20, 40, 80, and 160 seconds
Number of subjects: 17
Study 22130395 — intervention group
Group type: EXPERIMENTAL
Intervention: Recovery after a maximal 30‐second sprint
Number of subjects: 17
Study 22130395 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived recovery via visual analog scales
Number of subjects: 17
Study 22130395 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived recovery
Number of subjects: 17
Study 20668969 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini-incision posterior approach
Number of subjects: 72
Study 20668969 — intervention group
Group type: COMPARATOR
Intervention: Two-incision approach
Number of subjects: 72
Study 17346333 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepped-care programme for prevention of depressive and anxiety disorders
Number of subjects: 0
Study 16137243 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent calculation task
Number of subjects: 32
Study 16137243 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent language task
Number of subjects: 32
Study 16137243 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent motor task
Number of subjects: 32
Study 16137243 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual cues
Number of subjects: 32
Study 11887047 — intervention group
Group type: EXPERIMENTAL
Intervention: Tepid blood cardioplegia with mild systemic hypothermia (33 degrees C)
Number of subjects: 154
Study 11887047 — intervention group
Group type: COMPARATOR
Intervention: Cold blood cardioplegia with moderate systemic hypothermia (27 degrees C)
Number of subjects: 154
Study 11887047 — intervention group
Group type: EXPERIMENTAL
Intervention: Both strategies of myocardial protection
Number of subjects: 154
Study 10094221 — intervention group
Group type: EXPERIMENTAL
Intervention: Suplatast tosilate and bufexamac ointment
Number of subjects: 32
Study 10094221 — intervention group
Group type: COMPARATOR
Intervention: Bufexamac ointment (Control)
Number of subjects: 32
Study 7785162 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravascular laser irradiation (ILR)
Number of subjects: 16
Study 2276321 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg calcium supplementation
Number of subjects: 254
Study 2276321 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 254
Study 6776555 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventilated cigarette holders with varying tobacco product concentrations (100% to 10%)
Number of subjects: 0
Study 30998747 — intervention group
Group type: EXPERIMENTAL
Intervention: 81mg of aspirin + 400mcg of folic acid
Number of subjects: 1228
Study 30998747 — intervention group
Group type: COMPARATOR
Intervention: Placebo + 400mcg of folic acid
Number of subjects: 1228
Study 27267403 — intervention group
Group type: COMPARATOR
Intervention: DDX58_rs10813831 T-allele in EBV-positive cHL patients
Number of subjects: 275
Study 27267403 — intervention group
Group type: COMPARATOR
Intervention: Stratified analysis of DDX58_rs10813831 T-allele
Number of subjects: 275
Study 25542911 — intervention group
Group type: EXPERIMENTAL
Intervention: E-cigarette users
Number of subjects: 2123
Study 25542911 — intervention group
Group type: EXPERIMENTAL
Intervention: E-cigarette use
Number of subjects: 2123
Study 24512527 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 months i.m. leuprorelin (androgen suppression) before radiotherapy
Number of subjects: 1071
Study 24512527 — intervention group
Group type: EXPERIMENTAL
Intervention: 18 months zoledronic acid (ZdA)
Number of subjects: 1071
Study 24512527 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 and 18 months of androgen suppression (AS)
Number of subjects: 1071
Study 24512527 — intervention group
Group type: EXPERIMENTAL
Intervention: Androgen suppression duration
Number of subjects: 1071
Study 24512527 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid (ZdA)
Number of subjects: 1071
Study 22350761 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-assisted medication reconciliation
Number of subjects: 423
Study 21147705 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed fiber diet
Number of subjects: 34
Study 21147705 — intervention group
Group type: COMPARATOR
Intervention: Non-fiber diet
Number of subjects: 34
Study 17991555 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback therapy
Number of subjects: 121
Study 17991555 — intervention group
Group type: COMPARATOR
Intervention: Timed voiding (Control)
Number of subjects: 121
Study 15663545 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetate-free biofiltration (AFB)
Number of subjects: 8
Study 15663545 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicarbonate hemodialysis (BCD)
Number of subjects: 8
Study 15663545 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemodiafiltration (HDF)
Number of subjects: 8
Study 11950246 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine 0.5 mg twice daily
Number of subjects: 39
Study 11950246 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 9788453 — intervention group
Group type: EXPERIMENTAL
Intervention: Alteplase (0.9 mg/kg bodyweight)
Number of subjects: 800
Study 9788453 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 800
Study 7622291 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat dietary intervention (20% of total caloric intake from fat)
Number of subjects: 101
Study 7622291 — intervention group
Group type: COMPARATOR
Intervention: Control group (38% of caloric intake as fat, no dietary changes)
Number of subjects: 101
Study 2523870 — intervention group
Group type: EXPERIMENTAL
Intervention: ramipril (5 mg)
Number of subjects: 12
Study 2523870 — intervention group
Group type: EXPERIMENTAL
Intervention: captopril (12.5 mg)
Number of subjects: 12
Study 2523870 — intervention group
Group type: EXPERIMENTAL
Intervention: ramipril
Number of subjects: 12
Study 2523870 — intervention group
Group type: EXPERIMENTAL
Intervention: captopril
Number of subjects: 12
Study 6256510 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole
Number of subjects: 102
Study 6256510 — intervention group
Group type: COMPARATOR
Intervention: Control (no levamisole)
Number of subjects: 102
Study 6256510 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole stimulation in rats
Number of subjects: 102
Study 6256510 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of active immunization and adjuvant stimulation with bacillus Calmette-Guerin plus levamisole
Number of subjects: 102
Study 31069457 — intervention group
Group type: EXPERIMENTAL
Intervention: Total fat intake (highest versus lowest tertile)
Number of subjects: 1181
Study 31069457 — intervention group
Group type: EXPERIMENTAL
Intervention: Monounsaturated fatty acids
Number of subjects: 1181
Study 31069457 — intervention group
Group type: EXPERIMENTAL
Intervention: Substituting polyunsaturated fats with monounsaturated fats while maintaining total fat intake
Number of subjects: 1181
Study 31069457 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate intake of monounsaturated fatty acids
Number of subjects: 1181
Study 31069457 — intervention group
Group type: EXPERIMENTAL
Intervention: High intake of monounsaturated fatty acids
Number of subjects: 1181
Study 30481720 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiplex microarray-based component resolved diagnosis (CRD) using ISAC
Number of subjects: 57
Study 30481720 — intervention group
Group type: COMPARATOR
Intervention: Singleplex ImmunoCAP
Number of subjects: 57
Study 30481720 — intervention group
Group type: EXPERIMENTAL
Intervention: ISAC
Number of subjects: 57
Study 27743855 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based exercise program, three times per week for eight weeks
Number of subjects: 32
Study 27743855 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 32
Study 27743855 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (EG)
Number of subjects: 32
Study 25997548 — intervention group
Group type: EXPERIMENTAL
Intervention: NRL972 (Fluorescein Lisicol) 2 mg IV injection
Number of subjects: 55
Study 23552786 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality scale for removable partial dentures (RPD) applied by technicians familiar with the scale.
Number of subjects: 4
Study 23552786 — intervention group
Group type: COMPARATOR
Intervention: Control group with no feedback information provided.
Number of subjects: 4
Study 20093968 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycle sprints before UPLS workout
Number of subjects: 30
Study 20093968 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycle sprints before LPUS workout
Number of subjects: 30
Study 20093968 — intervention group
Group type: COMPARATOR
Intervention: Control sessions (no sprints)
Number of subjects: 30
Study 20093968 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower-body cycle sprint
Number of subjects: 30
Study 20093968 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper-body cycle sprint
Number of subjects: 30
Study 20093968 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of workout differences in Sal-T and Sal-C concentrations
Number of subjects: 30
Study 19383227 — intervention group
Group type: EXPERIMENTAL
Intervention: Double aortic clamping (group 1)
Number of subjects: 120
Study 19383227 — intervention group
Group type: COMPARATOR
Intervention: Single aortic clamping (group 2)
Number of subjects: 120
Study 19383227 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (double and single clamping)
Number of subjects: 120
Study 19690247 — intervention group
Group type: EXPERIMENTAL
Intervention: IBW (Ideal Body Weight) group, n = 17
Number of subjects: 51
Study 19690247 — intervention group
Group type: EXPERIMENTAL
Intervention: CBW20% (Corrected Body Weight plus 20% of excess weight) group, n = 17
Number of subjects: 51
Study 19690247 — intervention group
Group type: EXPERIMENTAL
Intervention: CBW40% (Corrected Body Weight plus 40% of excess weight) group, n = 17
Number of subjects: 51
Study 19690247 — intervention group
Group type: COMPARATOR
Intervention: IBW group
Number of subjects: 51
Study 19690247 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 51
Study 15195596 — intervention group
Group type: EXPERIMENTAL
Intervention: IgY stomat-spray (30 doses, 6 times daily, titer = 512)
Number of subjects: 50
Study 15195596 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 15195596 — intervention group
Group type: EXPERIMENTAL
Intervention: IgY stomat-spray (open label trial)
Number of subjects: 50
Study 11773155 — intervention group
Group type: EXPERIMENTAL
Intervention: Nausea/Vomiting (N/V) burden estimation using LASA indicators
Number of subjects: 249
Study 11773155 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment burden estimation using LASA indicators
Number of subjects: 249
Study 9404372 — intervention group
Group type: EXPERIMENTAL
Intervention: Frusemide (4 ml x 10 mg/ml)
Number of subjects: 12
Study 9404372 — intervention group
Group type: COMPARATOR
Intervention: Placebo (isotonic saline)
Number of subjects: 12
Study 8256357 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized hospital practice (PHP)
Number of subjects: 100
Study 8256357 — intervention group
Group type: COMPARATOR
Intervention: Standard hospital practice (Control)
Number of subjects: 100
Study 3442947 — intervention group
Group type: EXPERIMENTAL
Intervention: Lignocaine
Number of subjects: 30
Study 3442947 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 30
Study 11519503 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel (300 mg immediately, followed by 75 mg once daily)
Number of subjects: 12562
Study 11519503 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12562
Study 31368137 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous care using mobile health application
Number of subjects: 120
Study 31368137 — intervention group
Group type: COMPARATOR
Intervention: Conventional care
Number of subjects: 120
Study 29937253 — intervention group
Group type: EXPERIMENTAL
Intervention: Links to Learning (L2L) model for referred, disruptive students
Number of subjects: 136
Study 29937253 — intervention group
Group type: COMPARATOR
Intervention: Services and professional development as usual (SAU)
Number of subjects: 136
Study 26907087 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine monohydrate (CM) 2g daily for 8 weeks
Number of subjects: 0
Study 26907087 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine monohydrate (CM) 4g daily for 8 weeks
Number of subjects: 0
Study 26907087 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine monohydrate (CM) 10g daily for 8 weeks
Number of subjects: 0
Study 26907087 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 26907087 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall sample (CM and placebo)
Number of subjects: 0
Study 24812104 — intervention group
Group type: EXPERIMENTAL
Intervention: CICADA method
Number of subjects: 162
Study 22634536 — intervention group
Group type: EXPERIMENTAL
Intervention: RHES+radiotherapy
Number of subjects: 50
Study 22634536 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 50
Study 20433803 — intervention group
Group type: EXPERIMENTAL
Intervention: FSME-IMMUN Junior
Number of subjects: 303
Study 20433803 — intervention group
Group type: COMPARATOR
Intervention: Encepur Children
Number of subjects: 303
Study 20433803 — intervention group
Group type: EXPERIMENTAL
Intervention: Both vaccines
Number of subjects: 303